Browse diseases

…xpression correlated with anti-PD-1 resistance in patients with melanoma. KLRG1 knockout mice showed significantly reduced tumor growth,…

…portance Ipilimumab–nivolumab combination has reshaped advanced melanoma management, improving survival. Nevertheless, dual checkpoint b…

…nclusion and Relevance Immunotherapy has significantly improved melanoma prognosis, albeit at high drug-related costs. In the adjuvant s…

… factor) and signal 2s (4-1BBL, CD80, CD86, or OX40L) to B16F10 melanoma tumors in vivo. Downstream immune responses and impact on the T…

… not statistically significant after adjusting for confounders. Melanoma emerges as a distinct outlier, with Western cohorts showing dis…

…d; the mean age was 67.6±13.6 years. The primary diagnoses were Renal Cell Carcinoma (31%), Bladder Cancer (31%), and Melanoma (38%). 65 patients (4…

…B response in eight new and diverse clinical cohorts; including melanoma, NSCLC, breast, renal, bladder, and HNSCC; with a mean AUC of 0…

…as revolutionised the treatment of cancers such as Melanoma and non-small cell lung cancer. However, many patients do not respond to ICB whilst some cance…

…66 (49%) had GI cancer, 82 (15%) had lung cancer, 117 (21%) had melanoma, 38 (7%) had NMSC, and 43 (8%) had uterine cancer. rwORR was si…

… and had gradually acquired an effector-memory phenotype. Human melanoma TIL showed robust CAR expression (>80%) following transduction,…

… each segment in liver TIL harvest for ACT in 158 patients with metastatic melanoma and epithelial cancers…

…ining TIL-ACT with ANV419 in patients with metastatic cutaneous melanoma refractory to standard systemic therapies. Ten patients receive…